Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2010

View Archived Issues

Daiichi Sankyo claims new ligands of voltage-dependent calcium channel subunit alpha2-delta

University of Ulsan identifies new anticancer prodrugs

Phase III panitumumab trial in head and neck cancer does not meet primary endpoint

NeoStem and Schepens Eye Research Institute enter agreement for retinal diseases

Ustekinumab yields sustained response in phase II and III trials in plaque psoriasis

Israeli scientists describe new muscarinic acetylcholine M1 receptor modulators

Italian researchers present new NS5B inhibitors

Bristol-Myers Squibb claims new S1P1 receptor agonists

PregLem inlicenses bentamapimod from Merck Serono for postoperative adhesions and endometriosis

Abobotulinumtoxin A rapidly reduces glabellar lines in phase III trials

Cannabinoids show promise in models of inflammation and bone loss

New clindamycin/tretinoin gel more effective than constituents in treating acne

SLC40A1 is a marker of breast cancer prognosis

Onabotulinumtoxin A is safe and efficacious in women with vertical lip columns

Vyteris reports phase II data on transdermal patch for female infertility

Agile Therapeutics begins phase III trial of contraceptive patch AG-200-15

Astex and Multiple Myeloma Research Consortium start phase II AT-7519 trial

FDA advisory committee votes in favor of ezogabine

Labopharm launches Oleptro in U.S. for major depressive disorder

Mologen reports results for first half of 2010

PMX-60056 shows promise as heparin activity-reversing agent in phase Ib/II trial

PSI-7977 receives FDA fast track status for chronic HCV infection

FDA grants orphan status to becaplermin in osteochondritis dissecans

FDA warns of risk of aseptic meningitis associated with Lamictal use

European Commission grants orphan status to bosutinib in CML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...